

# Determinants of quality of life in pediatric- and adult-onset multiple sclerosis

Kyla A. McKay, PhD, Olivia Ernstsson, MSc, Ali Manouchehrinia, PhD, et al.

Cite as: *Neurology*® 2020;94:e932-e941. doi:10.1212/WNL.00000000000008667

## Correspondence

Dr. McKay  
kyla.mckay@ki.se

## Study objective and summary result

This study of patients with multiple sclerosis (MS) tested the hypothesis that the quality of life (QoL) impairments of adults with pediatric-onset MS (POMS) are greater than those of adults with adult-onset MS (AOMS). The results, however, showed that POMS and AOMS are associated with similarly severe QoL impairments.

## What is known and what this paper adds

Relative to patients with AOMS, patients with POMS exhibit greater cognitive impairment levels and reach disability milestones at earlier ages. However, this investigation provides evidence against the existence of any difference in QoL impairment severities.

## Participants and setting

The investigators analyzed data from 354 adults with POMS (71.5% female; mean age, 27.36 ± 7.66 years) and 4,740 adults with AOMS (69.9% female; mean age, 36.93 ± 7.40 years) who were listed in the Swedish MS Registry, which collects data from throughout Sweden. The selected individuals had disease durations of <35 years.

## Design, size, and duration

Cohort study with an average follow-up time of 3 years.

## Primary outcome measures

The patients underwent QoL assessments with the EQ-5D, which includes the EQ visual analogue scale (EQ-VAS). Linear mixed models were used to compare the POMS and AOMS groups in terms of EQ-VAS scores.

## Main results and the role of chance

The POMS and AOMS groups were similar in terms of EQ-VAS scores ( $\beta$ -coefficient for POMS group vs AOMS group, 0.99; 95% confidence interval, 0.89–2.87).

**Table** Comparisons of the POMS and AOMS groups in terms of specific EQ-5D domains

EQ-5D domain	Adjusted odds ratio (95% confidence interval) for reporting problems in the POMS group vs the AOMS group
Mobility	1.57 (0.81–3.06)
Self-care	0.37 (0.11–1.23)
Usual activities	0.88 (0.59–1.30)
Pain/discomfort	0.84 (0.58–1.22)
Anxiety/depression	0.71 (0.53–0.95)

## Bias, confounding, and other reasons for caution

Although the present study included a relatively large number of patients with POMS, it might still have been underpowered for detecting differences within the POMS group.

## Generalizability to other populations

The present study's focus on Sweden may limit the generalizability of the results to dissimilar countries.

## Study funding/potential competing interests

This study was funded by the Swedish Research Council, the Swedish Brain Foundation, the Canadian Institutes of Health Research, and the European Committee for Treatment and Research in MS. Some authors report receiving lecture honoraria, committee appointments, and funding from healthcare companies; serving as investigators on industry-sponsored projects; and receiving funding from Region Stockholm. Go to [Neurology.org/N](http://Neurology.org/N) for full disclosures.

*A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The corresponding author(s) of the full-length article and the journal editors edited and approved the final version.*

# Neurology®

## Determinants of quality of life in pediatric- and adult-onset multiple sclerosis

Kyla A. McKay, Olivia Ernstsson, Ali Manouchehrinia, et al.

*Neurology* 2020;94:e932-e941 Published Online before print November 15, 2019

DOI 10.1212/WNL.00000000000008667

### This information is current as of November 15, 2019

<b>Updated Information &amp; Services</b>	including high resolution figures, can be found at: <a href="http://n.neurology.org/content/94/9/e932.full">http://n.neurology.org/content/94/9/e932.full</a>
<b>References</b>	This article cites 29 articles, 7 of which you can access for free at: <a href="http://n.neurology.org/content/94/9/e932.full#ref-list-1">http://n.neurology.org/content/94/9/e932.full#ref-list-1</a>
<b>Subspecialty Collections</b>	This article, along with others on similar topics, appears in the following collection(s): <b>All Pediatric</b> <a href="http://n.neurology.org/cgi/collection/all_pediatric">http://n.neurology.org/cgi/collection/all_pediatric</a> <b>Multiple sclerosis</b> <a href="http://n.neurology.org/cgi/collection/multiple_sclerosis">http://n.neurology.org/cgi/collection/multiple_sclerosis</a> <b>Quality of life</b> <a href="http://n.neurology.org/cgi/collection/quality_of_life">http://n.neurology.org/cgi/collection/quality_of_life</a>
<b>Permissions &amp; Licensing</b>	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: <a href="http://www.neurology.org/about/about_the_journal#permissions">http://www.neurology.org/about/about_the_journal#permissions</a>
<b>Reprints</b>	Information about ordering reprints can be found online: <a href="http://n.neurology.org/subscribers/advertise">http://n.neurology.org/subscribers/advertise</a>

*Neurology*® is the official journal of the American Academy of Neurology. Published continuously since 1951, it is now a weekly with 48 issues per year. Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. All rights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.

